Evaluation of AHCC® for the Clearance of High Risk-HPV Infections in Chinese Female
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This is a multi-centre, randomised, double blind, placebo-controlled study on female
participants with diagnosis of high-risk human papillomavirus (HR-HPV) infection to evaluate
the clearance capacity of AHCC®.